IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer
Background - Immune checkpoint inhibitors improve the efficacy of first-line chemotherapy for patients with programmed death-ligand 1 (PD-L1)-positive unresectable locally advanced/metastatic triple-negative breast cancer (aTNBC), but randomised data in rapidly relapsing aTNBC are scarce. - Patients...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 2024
|
| In: |
Annals of oncology
Year: 2024, Jahrgang: 35, Heft: 7, Pages: 630-642 |
| ISSN: | 1569-8041 |
| DOI: | 10.1016/j.annonc.2024.04.001 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.annonc.2024.04.001 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0923753424001078 
|
| Verfasserangaben: | R. Dent, F. André, A. Gonçalves, M. Martin, P. Schmid, F. Schütz, S. Kümmel, S.M. Swain, A. Bilici, D. Loirat, R. Villalobos Valencia, S.-A. Im, Y.H. Park, M. De Laurentis, M. Colleoni, V. Guarneri, G. Bianchini, H. Li, Z. Kirchmayer Machackova, J. Mouta, R. Deurloo, X. Gan, M. Fan, A. Mani, A. Swat & J. Cortés |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1908294779 | ||
| 003 | DE-627 | ||
| 005 | 20241220171141.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241112s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2024.04.001 |2 doi | |
| 035 | |a (DE-627)1908294779 | ||
| 035 | |a (DE-599)KXP1908294779 | ||
| 035 | |a (OCoLC)1475647335 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Dent, Rebecca |e VerfasserIn |0 (DE-588)1348039159 |0 (DE-627)1908295465 |4 aut | |
| 245 | 1 | 0 | |a IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer |c R. Dent, F. André, A. Gonçalves, M. Martin, P. Schmid, F. Schütz, S. Kümmel, S.M. Swain, A. Bilici, D. Loirat, R. Villalobos Valencia, S.-A. Im, Y.H. Park, M. De Laurentis, M. Colleoni, V. Guarneri, G. Bianchini, H. Li, Z. Kirchmayer Machackova, J. Mouta, R. Deurloo, X. Gan, M. Fan, A. Mani, A. Swat & J. Cortés |
| 264 | 1 | |c July 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 15. Mai 2024, Artikelversion: 21. Juni 2024 | ||
| 500 | |a Gesehen am 12.11.2024 | ||
| 520 | |a Background - Immune checkpoint inhibitors improve the efficacy of first-line chemotherapy for patients with programmed death-ligand 1 (PD-L1)-positive unresectable locally advanced/metastatic triple-negative breast cancer (aTNBC), but randomised data in rapidly relapsing aTNBC are scarce. - Patients and methods - IMpassion132 (NCT03371017) enrolled patients with aTNBC relapsing <12 months after last chemotherapy dose (anthracycline and taxane required) or surgery for early TNBC. PD-L1 status was centrally assessed using SP142 before randomisation. Initially patients were enrolled irrespective of PD-L1 status. From August 2019, enrolment was restricted to PD-L1-positive (tumour immune cell ≥1%) aTNBC. Patients were randomised 1:1 to placebo or atezolizumab 1200 mg every 21 days with investigator-selected chemotherapy until disease progression or unacceptable toxicity. Stratification factors were chemotherapy regimen (carboplatin plus gemcitabine or capecitabine monotherapy), visceral (lung and/or liver) metastases and (initially) PD-L1 status. The primary endpoint was overall survival (OS), tested hierarchically in patients with PD-L1-positive tumours and then, if positive, in the modified intent-to-treat (mITT) population (all-comer patients randomised pre-August 2019). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR) and safety. - Results - Among 354 patients with rapidly relapsing PD-L1-positive aTNBC, 68% had a disease-free interval of <6 months and 73% received carboplatin/gemcitabine. The OS hazard ratio was 0.93 (95% confidence interval 0.73-1.20, P = 0.59; median 11.2 months with placebo versus 12.1 months with atezolizumab). mITT and subgroup results were consistent. Median PFS was 4 months across treatment arms and populations. ORRs were 28% with placebo versus 40% with atezolizumab. Adverse events (predominantly haematological) were similar between arms and as expected with atezolizumab plus carboplatin/gemcitabine or capecitabine following recent chemotherapy exposure. - Conclusions - OS, which is dismal in patients with TNBC relapsing within <12 months, was not improved by adding atezolizumab to chemotherapy. A biology-based definition of intrinsic resistance to immunotherapy in aTNBC is urgently needed to develop novel therapies for these patients in next-generation clinical trials. | ||
| 650 | 4 | |a disease-free interval | |
| 650 | 4 | |a immune checkpoint | |
| 650 | 4 | |a PD-L1 | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a rapid relapse | |
| 650 | 4 | |a triple-negative breast cancer | |
| 700 | 1 | |a André, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gonçalves, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Martin, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmid, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schütz, Florian |d 1972- |e VerfasserIn |0 (DE-588)12303387X |0 (DE-627)082307229 |0 (DE-576)293528810 |4 aut | |
| 700 | 1 | |a Kümmel, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Swain, S. M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bilici, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loirat, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Villalobos Valencia, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Im, S. -A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Park, Y. H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a De Laurentis, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Colleoni, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Guarneri, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bianchini, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Li, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kirchmayer Machackova, Z. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mouta, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Deurloo, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gan, X. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fan, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mani, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Swat, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cortés, J. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 35(2024), 7 vom: Juli, Seite 630-642 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer |
| 773 | 1 | 8 | |g volume:35 |g year:2024 |g number:7 |g month:07 |g pages:630-642 |g extent:13 |a IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.annonc.2024.04.001 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0923753424001078 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241112 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 12303387X |a Schütz, Florian |m 12303387X:Schütz, Florian |d 50000 |e 50000PS12303387X |k 0/50000/ |p 6 | ||
| 999 | |a KXP-PPN1908294779 |e 4613345235 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"part":{"volume":"35","text":"35(2024), 7 vom: Juli, Seite 630-642","pages":"630-642","year":"2024","extent":"13","issue":"7"},"recId":"320428796","title":[{"subtitle":"official journal of the European Society for Medical Oncology","title":"Annals of oncology","title_sort":"Annals of oncology"}],"origin":[{"publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","dateIssuedDisp":"1990-","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedKey":"1990"}],"pubHistory":["1.1990 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"issn":["1569-8041"],"eki":["320428796"],"zdb":["2003498-2"]},"language":["eng"],"corporate":[{"role":"isb","display":"European Society for Medical Oncology"}],"disp":"IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancerAnnals of oncology","physDesc":[{"extent":"Online-Ressource"}]}],"note":["Online verfügbar: 15. Mai 2024, Artikelversion: 21. Juni 2024","Gesehen am 12.11.2024"],"recId":"1908294779","person":[{"role":"aut","display":"Dent, Rebecca","given":"Rebecca","family":"Dent"},{"family":"André","display":"André, F.","given":"F.","role":"aut"},{"role":"aut","family":"Gonçalves","display":"Gonçalves, A.","given":"A."},{"given":"M.","display":"Martin, M.","family":"Martin","role":"aut"},{"family":"Schmid","given":"P.","display":"Schmid, P.","role":"aut"},{"role":"aut","family":"Schütz","display":"Schütz, Florian","given":"Florian"},{"family":"Kümmel","given":"S.","display":"Kümmel, S.","role":"aut"},{"family":"Swain","given":"S. M.","display":"Swain, S. M.","role":"aut"},{"role":"aut","family":"Bilici","display":"Bilici, A.","given":"A."},{"role":"aut","family":"Loirat","display":"Loirat, D.","given":"D."},{"role":"aut","family":"Villalobos Valencia","display":"Villalobos Valencia, R.","given":"R."},{"role":"aut","family":"Im","given":"S. -A.","display":"Im, S. -A."},{"role":"aut","display":"Park, Y. H.","given":"Y. H.","family":"Park"},{"given":"M.","display":"De Laurentis, M.","family":"De Laurentis","role":"aut"},{"role":"aut","given":"M.","display":"Colleoni, M.","family":"Colleoni"},{"family":"Guarneri","given":"V.","display":"Guarneri, V.","role":"aut"},{"family":"Bianchini","given":"G.","display":"Bianchini, G.","role":"aut"},{"given":"H.","display":"Li, H.","family":"Li","role":"aut"},{"role":"aut","given":"Z.","display":"Kirchmayer Machackova, Z.","family":"Kirchmayer Machackova"},{"display":"Mouta, J.","given":"J.","family":"Mouta","role":"aut"},{"display":"Deurloo, R.","given":"R.","family":"Deurloo","role":"aut"},{"role":"aut","display":"Gan, X.","given":"X.","family":"Gan"},{"role":"aut","given":"M.","display":"Fan, M.","family":"Fan"},{"given":"A.","display":"Mani, A.","family":"Mani","role":"aut"},{"role":"aut","family":"Swat","display":"Swat, A.","given":"A."},{"display":"Cortés, J.","given":"J.","family":"Cortés","role":"aut"}],"origin":[{"dateIssuedDisp":"July 2024","dateIssuedKey":"2024"}],"title":[{"title":"IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer","title_sort":"IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1908294779"],"doi":["10.1016/j.annonc.2024.04.001"]},"language":["eng"],"name":{"displayForm":["R. Dent, F. André, A. Gonçalves, M. Martin, P. Schmid, F. Schütz, S. Kümmel, S.M. Swain, A. Bilici, D. Loirat, R. Villalobos Valencia, S.-A. Im, Y.H. Park, M. De Laurentis, M. Colleoni, V. Guarneri, G. Bianchini, H. Li, Z. Kirchmayer Machackova, J. Mouta, R. Deurloo, X. Gan, M. Fan, A. Mani, A. Swat & J. Cortés"]},"physDesc":[{"extent":"13 S.","noteIll":"Illustrationen"}]} | ||
| SRT | |a DENTREBECCIMPASSION12024 | ||